Different doses of gemcitabine chemotherapy after radical resection of pancreatic cancer:a randomized controlled clinical study

YU Xu-ping

doi:10.13406/j.cnki.cyxb.2010.03.026

您当前的位置：

首页 >

文章列表页 >

Different doses of gemcitabine chemotherapy after radical resection of pancreatic cancer:a randomized controlled clinical study

更新时间：2024-01-17

- Different doses of gemcitabine chemotherapy after radical resection of pancreatic cancer:a randomized controlled clinical study
- Journal of Chongqing Medical University Vol. 35, Issue 3, Pages: 436-439(2010)
- 作者机构：
  
  湖南省邵阳市中心医院普外科
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2010.03.026
  CLC： R735.9
- Published：2010，
扫描看全文
[1]禹旭平.不同剂量吉西他滨辅助化疗根治术后胰腺癌的随机对照临床研究[J].重庆医科大学学报,2010,35(03):436-439.

YU Xu-ping. Different doses of gemcitabine chemotherapy after radical resection of pancreatic cancer:a randomized controlled clinical study. [J]. Journal of Chongqing Medical University 35(3):436-439(2010)
[1]禹旭平.不同剂量吉西他滨辅助化疗根治术后胰腺癌的随机对照临床研究[J].重庆医科大学学报,2010,35(03):436-439. DOI： 10.13406/j.cnki.cyxb.2010.03.026.

YU Xu-ping. Different doses of gemcitabine chemotherapy after radical resection of pancreatic cancer:a randomized controlled clinical study. [J]. Journal of Chongqing Medical University 35(3):436-439(2010) DOI： 10.13406/j.cnki.cyxb.2010.03.026.

摘要

目的:比较标准剂量和小剂量吉西他滨对根治术后胰腺癌辅助化疗的疗效及安全性。方法:采用随机双盲平行对照的临床试验方法

以疾病相关症状改善、生存分析及毒副反应为结局终点指标

比较标准剂量（1000mg/m2）和小剂量（500mg/m2）吉西他滨辅助化疗根治术后胰腺癌的疗效及安全性。结果:2005年1月至2007年3月间符合标准的患者共83例

随机分组后患者性别、年龄等具有基线可比性（P>0.05）。意向性治疗分析和方案分析均显示标准剂量组和小剂量组疾病相关症状改善及术后生存均相当（P>0.05）

而毒副反应

尤其是血液系统毒性在标准剂量组高于小剂量组（P<0.05）。结论:小剂量吉西他滨对根治术后胰腺癌辅助化疗的疗效和标准剂量相当

而毒副反应减少。

Abstract

Objective:To compare standard-dose and low-dose gemcitabine adjuvant chemotherapy for pancreatic cancer after radical operation

assessing its efficacy and safety.Methods:A randomized double-blind

parallel-controlled clinical trial was used in this study

disease-related symptoms improved

survival analysis and toxicity as the end point for the outcome indicators to compare standard-dose(1 000 mg/m2) and low-dose(500 mg/m2) gemcitabine adjuvant chemotherapy after radical resection of pancreatic cancer.Results:From January 2005 to March 2007

83 patients who meet the criteria were enrolled in the study.The baseline in two groups was the same(P> 0.05).Intention to treat analysis and per-protocol analysis have shown that disease-related symptom improvement and survival were the same in two groups(P>0.05)

but toxicity

especially hematologic toxicity in standard-dose group was higher than that in the low-dose group(P<0.05).Conclusion:Low-dose gemcitabine was efficacy for pancreatic cancer after radical resection

but the toxicity reduced compared with standard-dose chemotherapy.

关键词

胰腺癌根治术化疗吉西他滨随机对照临床研究

Keywords

pancreatic cancerRadical resection of pancreatic cancerchemotherapygemcitabineRandomized controlled clinical study

references

Views

130

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative study of gemcitabine plus CBP and navelbine plus DDP regimen in the treatment of old patients with age NSCLC

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Efficacy of transurethral submucosal dissection of bladder tumor combined with intraoperative bladder submucosal injection of gemcitabine in treatment of non-muscle invasive urothelial bladder cancer: a report of seven cases

Mechanism of anthrax toxin receptor 2 expression regulated by miR-145-5p in pancreatic cancer

Effect of progressive muscle relaxation training on coping style and emotion of patients with lung cancer

Related Author

JIANG Youfan

et al

兰箭

Xu Qiao

Jiang Yu

Wan Shihao

He Yunfeng

Tang Ruipeng

Related Institution

重庆医科大学附属第二医院呼吸科

Department of Respiratory Disease,the Second Affiliated Hospital,Chongqing Medical University

Department of Urology，The First Affiliated Hospital of Chongqing Medical University

Department of Urology，Pangang Group General Hospital

Second Department of Hepatobiliary Surgery，Institute of Hepatobiliary，Pancreatic and Intestine， North Sichuan Medical College

⁰